Pulmonary Fibrosis Treatment

Once idiopathic pulmonary fibrosis (IPF) or another progressive form of interstitial lung disease (ILD) is diagnosed, treatment becomes an ongoing, individualized process rather than a single decision made once. This page goes deeper into how that treatment actually works: the specific antifibrotic drug classes and how they differ, practical management of their side effects, how therapy is monitored and adjusted over time, and how lung transplant evaluation and clinical trial participation fit into the picture.

What Treatment Aims to Do

There is currently no cure for IPF or for progressive fibrosing forms of ILD, and no available medication reverses scarring that has already developed. Treatment instead aims to slow the pace of further scarring, manage symptoms, and support function and quality of life over the course of the disease.

This page’s scope extends slightly beyond IPF specifically to cover progressive pulmonary fibrosis (PPF), a term describing chronic fibrosing ILD, including some non-IPF forms, that behaves in a progressive, IPF-like way over time. That distinction matters because it affects which medication options apply: one of the two antifibrotic drug classes has an FDA approval that extends to this broader progressive category, not only to IPF itself, which is a meaningful and relatively recent expansion of the treatment landscape.

Antifibrotic Medications: Two Distinct Drug Classes

Antifibrotic therapy is the backbone of pharmacologic treatment for IPF and PPF. Two FDA-approved drug classes exist, and while both are broadly described as “antifibrotics,” they work through genuinely different mechanisms.

Combining the two antifibrotics together is not standard practice. Instead, a pulmonologist selects one based on the specific diagnosis, expected tolerability, other medical conditions, and patient preference, with the option to switch if the first choice is not well tolerated or does not seem to be the right fit.

Managing Antifibrotic Side Effects

Both antifibrotics carry real side effects, and understanding them, along with practical ways to manage them, is central to staying on therapy long enough for it to help.

Common Side Effects and How They Are Managed

GI Symptoms with Pirfenidone

Nausea, diarrhea, decreased appetite, and dyspepsia are common, especially early on. Taking the medication with food and following the gradual dose-escalation schedule can meaningfully reduce these symptoms.

Photosensitivity with Pirfenidone

Increased sensitivity to sunlight can cause sunburn or a rash with sun exposure. Daily sunscreen, sun-protective clothing, and avoiding prolonged direct sun exposure are standard practical measures.

Diarrhea with Nintedanib

The most common side effect of nintedanib. It is often managed with dose timing adjustments, dietary changes, and antidiarrheal medication when needed, rather than automatically stopping the drug.

Liver Enzyme Elevation

Both medications can raise liver enzymes. Baseline liver function testing before starting either drug, followed by periodic monitoring during treatment, allows this to be caught and addressed early, sometimes with a temporary dose reduction or pause.

Nintedanib also carries a modest bleeding risk related to its effect on blood vessel signaling, so it is used cautiously in patients on certain blood-thinning medications, and it is generally avoided in pregnancy given its mechanism of action. Most side effects with either medication are manageable through these practical strategies rather than requiring treatment to be abandoned altogether, though a small number of patients do need to stop or switch therapy.

How Treatment Is Individualized and Monitored

Starting an antifibrotic is not a one-time decision made in isolation. Whether and when to start, which drug to choose, and how to adjust dosing over time are individualized based on the specific diagnosis, disease severity, other medical conditions, and how a patient tolerates the medication once started.

How Antifibrotic Therapy Is Followed Over Time

1. 01→Baseline AssessmentDiagnosis confirmation, baseline pulmonary function testing (including DLCO), and baseline liver function testing establish a starting point before therapy begins.↓
2. 02→Starting TherapyA chosen antifibrotic is started, often with a gradual dose-escalation schedule for pirfenidone, and early follow-up focuses on tolerability and side effects.↓
3. 03Routine MonitoringPeriodic pulmonary function testing tracks the trend in lung function over time, while routine blood work, particularly liver function tests, monitors for medication-related changes.↓
4. 04→Adjusting the ApproachBased on tolerability, side effects, and functional trends, the dose, timing, or choice of antifibrotic may be adjusted, or additional supportive therapies may be added.↓
5. 05Ongoing ReassessmentCare continues on a recurring basis for as long as therapy continues, since both the disease and a patient’s response to treatment can change over time.

This ongoing reassessment is what allows a pulmonologist to catch problems early, whether that means a side effect that needs a practical fix, a functional decline that raises the question of additional therapies, or a point where transplant evaluation or a clinical trial becomes worth discussing.

Supplemental Oxygen and Pulmonary Rehabilitation

Antifibrotic medication addresses the underlying fibrotic process, but it is only one part of a fuller treatment plan. Supplemental oxygen is introduced when testing confirms a clinically significant drop in blood oxygen saturation, particularly during exertion and, as disease progresses, at rest, and can meaningfully improve exercise tolerance and day-to-day comfort.

Pulmonary rehabilitation, a supervised program combining exercise training, breathing technique education, and energy conservation strategies, does not change the underlying fibrotic process, but it can meaningfully improve exercise capacity, symptom burden, and quality of life. Both are typically incorporated alongside, not instead of, antifibrotic therapy.

Lung Transplant Referral and Timing

For appropriately selected candidates, lung transplantation remains the one intervention that can replace severely scarred lung tissue rather than simply slowing further decline. Because evaluation and waitlisting can take a substantial amount of time, referral earlier in the disease course, well before transplant becomes an urgent need, is generally recommended rather than waiting until decline is advanced.

What Factors Into Transplant Candidacy and Timing

Disease Severity & Trajectory

Declining pulmonary function trends, worsening gas exchange, and the overall pace of progression all inform when referral is appropriate.

Overall Health

Other medical conditions, functional status, and general fitness for a major surgical procedure and its recovery are assessed individually.

Time-Sensitive Evaluation

The referral, evaluation, and waitlist process can take significant time, which is why earlier referral is generally favored over waiting for advanced decline.

Transplant evaluation is not an option or an appropriate step for every patient, and the decision to pursue it is made individually, in coordination between a patient’s pulmonology team and a transplant center.

Clinical Trial Participation

Because current antifibrotic therapy slows disease progression rather than reversing or curing it, clinical trial participation is a legitimate and, for many patients, worthwhile option to discuss. Trials may study new antifibrotic agents, combination treatment strategies, or other interventions aimed at further improving outcomes.

Eligibility criteria vary by trial, and whether a specific study fits a given patient’s diagnosis, disease stage, and overall health is a question best worked through with a pulmonologist familiar with both the individual’s case and the available trial landscape.

Getting Started

For patients in the North Dallas-Fort Worth area, the pulmonary team at VitalAir Sleep & Lung Center in Frisco, Texas offers evaluation and ongoing management for IPF and other forms of progressive pulmonary fibrosis, including antifibrotic therapy selection, side effect management, and coordination of supplemental oxygen, pulmonary rehabilitation, and transplant referral when appropriate.

The clinical information on this page applies regardless of where a patient lives; what a local evaluation adds is a physician-guided starting point and coordinated follow-up care close to home.